Matt Brow serves as the president and general manager of Inovalon’s Pharmacy, Life Sciences and Advisory business.
In this role, Matt leads the organization’s focus on bringing data-enabled strategic guidance and tools to the full array of healthcare companies – from pharmacy and life sciences, to managed care and providers. Unique to the Company’s data-driven advisory business, Avalere, and Inovalon’s cloud-based pharmacy platform business is the ability to combine analytical insights informed by billions of medical events with industry-leading subject matter and policy expertise, together powering configurations of the Inovalon ONE® Platform and ScriptMed® Platform to bring resulting solutions to the marketplace in large-scale. Matt has extensive experience managing cross-functional teams and has engaged internal and external healthcare stakeholders to find consensus and achieve stable business growth. Prior to his current role spanning Inovalon’s pharmacy, life sciences, and advisory services business, Matt was responsible for its Avalere advisory business.
Prior to joining Inovalon in 2017, Matt served as Senior Vice President of Operations, for the US Oncology Network at McKesson Specialty Health, and Vice President and General Manager of Vantage Oncology southeast region. Previously, Matt held roles at McKesson and its predecessor company, US Oncology, where he led public policy; mergers and acquisitions; business development; go-to-market strategy; sales; reimbursement strategy; federal and state government relations; and communications. Prior to joining US Oncology, he served as a consultant, advising clients on state government affairs strategy across a wide-range of healthcare and political issues.
Matt has published widely in peer-reviewed and professional journals on healthcare policy, the Affordable Care Act, cancer care quality, and value-based care. He holds a BA in history and political science from the University of Richmond.